摘要
目的观察重组人干扰素α2b联合甲强龙对喘息性支气管炎患儿嗜酸性粒细胞(EOS)、肺表面活性蛋白-D(SP-D)、25-羟维生素D_(3)[25-(OH)D_(3)]水平的影响。方法纳入2018年3月至2021年3月该院收治的喘息性支气管炎患儿99例,根据随机数字表法分为两组,对照组44例,观察组45例。对照组采用甲强龙治疗,观察组采用重组人干扰素α2b联合甲强龙治疗,均治疗6 d。观察两组患儿疗效、临床症状变化时间、EOS、SP-D、25-(OH)D_(3)水平变化及不良反应发生情况。结果观察组患儿治疗6 d后的临床总有效率明显高于对照组患儿(P<0.05)。观察组的喘息消失时间、咳嗽消失时间、气促缓解时间、肺部啰音消失时间和退热时间均短于对照组(P<0.05)。观察组治疗6 d后呼气峰流速(PEF)、用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))高于对照组(P<0.05)。观察组治疗6 d后EOS、SP-D水平低于对照组,25-(OH)D_(3)水平高于对照组(P<0.05)。对照组、观察组患儿的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论重组人干扰素α2b联合甲强龙治疗小儿喘息性支气管炎,可促进症状缓解,在改善肺功能、调节血清EOS、SP-D、25-(OH)D_(3)方面具有一定的优势。
Objective To observe recombinant human interferonα2b combined with methylprednisolone on the levels of eosinophils(EOS),pulmonary surfactant protein-D(SP-D)and 25 dihydroxyvitamin D_(3)[25-(OH)D_(3)]in asthmatic children.Methods From March 2018 to March 2021,99 children with asthmatic bronchus in our hospital were selected and divided into the control group(44 cases)and the observation group(45 cases).The control group treated with methylprednisolone while the observation group was treated with recombinant human interferonα2b combined with methylprednisolone,both group were treated for 6 days.The curative effect,clinical symptom change time,EOS,SP-D,25-(OH)D_(3) levels and adverse reactions of the two groups were observed.Results The clinical total effective rate of the observation group was significantly higher than that of the control group after 6 days of treatment(P<0.05).The disappearance time of wheezing,cough,shortness of breath,rales and fever in the observation group were shorter than those in the control group(P<0.05).The peak expiratory flow rate(PEF),forced vital capacity(FVC)and forced expiratory volume 1 in the first second(FEV_(1))in the observation group 6 days after treatment were higher than those in the control group(P<0.05).After treatment,levels of EOS and SP-D in the observation group were lower than those in the control group,and the level of 25-(OH)D_(3) in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the control group and the observation group(P>0.05).Conclusion Recombinant human interferonα2b combined with methylprednisolone in the treatment of asthmatic bronchi in children can promote symptom relief,and has certain advantages in improving lung function and regulating serum EOS,SP-D and 25-(OH)D_(3).
作者
连换杰
刘玉娇
邓娅君
LIAN Huanjie;LIU Yujiao;DENG Yajun(Second District of Department of Paediatrics,Taihe Hospital,Shiyan,Hubei 442000,China;Reproductive Medicine Centre,Taihe Hospital,Shiyan,Hubei 442000,China)
出处
《国际检验医学杂志》
CAS
2022年第12期1444-1447,共4页
International Journal of Laboratory Medicine
基金
湖北省十堰市科学技术研究与开发项目(18sj0741)。
